AZ Bets Big On ADCs As It Inks Second, $6bn Deal With Daiichi
$1bn Upfront To Secure New Asset
Following their original March 2019 tie-up for an oncology antibody-drug conjugate, Daiichi Sankyo and AstraZeneca have entered into a new global deal worth up to $6bn for a second novel asset from the Japanese firm, with potential in breast, lung and other cancers.
You may also be interested in...
Having established Enhertu as their first antibody-drug conjugate blockbuster, AstraZeneca and Daiichi Sankyo are looking to challenge Gilead in the TROP2-targeting field as well.
Phase III sub-analyses presented at ESMO show the drug providing a survival benefit in a complex subpopulation, as well as improvements to quality of life.
The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.